Teva Secures $400M Blackstone Funding for Duvakitug – TL1A Antibody Advances in IBD Phase III
Teva Pharmaceuticals (NYSE: TEVA) and Blackstone Life Sciences (BXLS) announced a $400 million strategic funding agreement over...
Blackstone Life Sciences
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...